DIRECTORS

Our Board consists of nine Directors, comprising two executive Directors, four non-executive Directors and three independent non-executive Directors. The following table sets out information in respect of our Directors:

Name	Age	Position	Date of joining our Company	Date of appointment as a Director	Roles and responsibilities	Relationship with other Directors and senior management
Dr. Jim Zhen WU.	63	Chairperson of the Board, executive Director and CEO	April 2014	April 2014	Overall management of the business strategy, corporate development and research and development of our Group	Dr. Wu is the spouse of Ms. Rao.
Dr. Mingyu JIANG (蔣鳴昱). . . .	39	Executive Director, Chief Financial Officer and Secretary of the Board	June 2025	September 2025	Overseeing the investments, financing and legal matters of our Group	N/A
Ms. Audrey RAO .	63	Non-executive Director	April 2014	September 2020	Providing guidance and advice on the corporate and business strategies	Ms. Rao is the spouse of Dr. Wu.
Dr. Kan CHEN (陳侃).	44	Non-executive Director	September 2025	September 2025	Providing guidance and advice on the corporate and business strategies	N/A
Dr. Liyang SHI (石莉揚). . . .	36	Non-executive Director	July 2022	July 2022	Providing guidance and advice on the corporate and business strategies	N/A
Ms. Chuheng LI (李楚衡). . . .	34	Non-executive Director	February 2025	February 2025	Providing guidance and advice on the corporate and business strategies	N/A
Dr. Ziye ZHAO (趙子夜). . . .	46	Independent non-executive Director	July 2025	July 2025	Supervising and providing independent judgment to our Board	N/A
Dr. Wenfang WU (吳文芳). . . .	47	Independent non-executive Director	March 2021[(2)]	July 2025	Supervising and providing independent judgment to our Board	N/A
Dr. Genhong CHENG	63	Independent non-executive Director	July 2025	July 2025	Supervising and providing independent judgment to our Board	N/A

Notes:

(1) Ages are calculated based on the year of birth.

(2) From March 2021 to March 2024, Dr. Wenfang WU served as an independent Director of our Company.

Executive Directors

Dr. Jim Zhen WU, founded our Company in April 2014 and has been serving as a Director, the chairperson of the Board and the CEO of our Company since then. He was re-designated as an executive Director in July 2025. Dr. Wu has also been serving as a director of all subsidiaries of our Company since their establishment.

Dr. Wu has over 30 years of experience in pharmaceutical research and development. Prior to founding our Group, Dr. Wu previously served as a senior scientist at Schering-Plough Research Institute (先靈葆雅研究院). Dr. Wu served as a director, pre-clinical and translational research at Valeant Pharmaceuticals International (formerly known as ICN Pharmaceuticals Inc.) from May 2000 to April 2008, a senior director in biology R&D department and virus R&D department of Roche R&D Center (China) Ltd. (羅氏研發(中國)有限公司) from May 2008 to June 2012, and July 2012 to July 2013, respectively. He worked for Sumo Biosciences LLC. and previously served as a director of Yagadol Pharmaceutical Technology Co., Ltd. (杭州雅克多醫藥科技有限公司) from November 2020 to January 2021 and the CEO of Sumo Biosciences LLC from August 2013 to April 2014.

Dr. Wu obtained his bachelor's degree and master's degree from University of Science and Technology of China (中國科學技術大學) in the PRC in July 1985 and October 1987, respectively. He obtained his doctoral degree from Brown University in the U.S. in May 1993. Dr. Wu was a post-doctoral fellow of the department of biological chemistry and molecular pharmacology of Harvard University Medical School in the U.S. from 1993 to 1995. Dr. Wu also served as a visiting professor at Fudan University Shanghai Medical College (復旦大學上海醫學院) from July 2012 to July 2014.

Dr. Mingyu JIANG (蔣鳴昱), has been serving as the chief financial officer and secretary of the Board since June 2025, and was appointed as the joint company secretary of our Company in July 2025 and an executive Director in September 2025.

Dr. Jiang has more than 13 years of experience in audits, risk management and equity research. From October 2009 to November 2011, he worked at KPMG Huazhen LLP (畢馬威華振會計師事務所), an accounting firm. From December 2011 to January 2013, he worked at KPMG Advisory (China) Co., Ltd. (畢馬威企業諮詢(中國)有限公司), a consultancy firm. From June 2015 to March 2018, he worked at Shanghai Pudong Science & Technology Investment Co., Ltd. (上海浦東科技投資有限公司), an investment and private equity firm. From March 2018 to July 2019, he worked at Zheshang Securities Co., Ltd. (浙商證券股份有限公司) (stock code: 601878 (SHSE)). Dr. Jiang is also a non-executive director of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (stock code: 2410 (HKSE)), where he previously served as an executive director, vice president, board secretary and joint company secretary from July 2019 to June 2025.

Dr. Jiang obtained his bachelor's degree in financial management from Shanghai University of International Business and Economics (上海對外經貿大學) in the PRC in July 2009. He obtained his master's degree in global finance from Fordham University in New York in May 2014. He further obtained his doctor's degree in pharmacoeconomics at China Pharmaceutical University (中國藥科大學) in the PRC in June 2024.

Dr. Jiang has been certified as a financial risk manager by the Global Association of Risk Professionals since September 2012. He was awarded as the Annual Best IPO CFO among 2024 Top 100 CFOs of Overseas Listed Companies (2024海外上市公司CFO百強榜年度最佳IPO CFO) and Best CFO of Ninth Zhitong Caijing Selection for Listed Companies (第九屆智通財經上市公司評選最佳CFO獎) in December 2024, and Forbes China 2025 Industry Innovation Leader (2025福布斯中國行業發展領創者) in March 2025.

Non-executive Directors

Ms. Audrey RAO, was re-designated as a non-executive Director in July 2025. She also served as a supervisor of our Company from April 2014 to September 2020.

Prior to joining our Group, Ms. Rao worked in various companies including but not limited to Prudential Insurance Company of America, HSBC Bank USA, Superior Bank, FSB, Countrywide Home Loans Inc. and Family Lending Services, INC.

Ms. Rao obtained her bachelor's degree in Chinese language and literature from Nanjing University (南京大學) in the PRC in July 1987 and her master's degree in business administration from Providence College in the U.S. in May 1994.

Dr. Kan CHEN (陳侃), was appointed as a non-executive Director in September 2025.

Dr. Chen brings in extensive experience bridging the realms of biotech entrepreneurship and venture investment. Dr. Chen has been with Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd. (啟明維創創業投資管理(上海)有限公司), focusing on healthcare management, since February 2016, currently serving as a partner. In his early career, from November 2012 to September 2014, Dr. Chen worked in the group of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (stock code: 600276 (SHSE) and 1276 (HKSE)). From September 2014 to January 2016, he worked at Johnson & Johnson (Shanghai) Medical Devices Co., Ltd. (強生(上海)醫療器材有限公司).

In addition to his directorship at our Company, Dr. Chen holds concurrent, or held, directorships in numerous healthcare companies, including (i) a director of InSilico Medicine Cayman TopCo (英矽智能) (stock code: 3696 (HKSE)) since August 2021 and was re-designated as its non-executive director in June 2023; (ii) a director of Abbisko Cayman Limited (和譽開曼有限責任公司) (stock code: 2256 (HKSE)) from February 2020 to June 2021; (iii) a director of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (江蘇亞虹醫藥科技有限公司) (stock code: 688176 (SHSE)) from October 2020 to December 2023; (iv) a director of CANbridge Pharmaceuticals Inc. (北海康成製藥有限公司) (stock code: 1228 (HKSE)) from December 2020 to September 2024; (v) a non-executive director of Connect Biopharma Holdings Limited (stock ticker/code: CNTB (NASDAQ)) from December 2020 to December 2025; and (vi) a non-executive director of Antengene Corporation Limited (德琪醫藥有限公司) (stock code: 6996 (HKSE)) from March 2021 to June 2024.

Dr. Chen obtained a Bachelor of Science degree in biological sciences from Fudan University in July 2004 and a doctoral degree of philosophy from Case Western Reserve University in the U.S. in January 2009. From September 2009 to October 2012, he served as research fellow in the department of pathology at Brigham and Women's Hospital of Harvard Medical School.

Dr. Liyang SHI (石莉揚), was re-designated as a non-executive Director in July 2025.

Dr. Shi previously worked as a counsel at Livzon Pharmaceutical Group Inc. (麗珠醫藥集團股份有限公司) (stock code: 000513 (SHSE) and 1513 (HKSE)), focusing on overseas projects assessment and introduction. From May 2020 to May 2021, she worked at Shenzhen Zhongnan Hongyuan Private Equity Venture Capital Fund Management Co., Ltd. (深圳中南弘遠私募創業投資基金管理有限公司). She has been working at Shanghai TF Venture Capital Management Co., Ltd (上海泰甫創業投資管理有限公司) since June 2021.

Dr. Shi obtained a bachelor's degree in pharmacy from Sichuan University (四川大學) in the PRC in June 2013 and a doctoral degree in chemistry (chemical genomics) from Peking University (北京大學) in the PRC in June 2019.

Ms. Chuheng LI (李楚衡), was re-designated as a non-executive Director in July 2025.

Ms. Li has nearly a decade of professional experience in investment management. Joining TPG Capital in January 2022, Ms. Li is currently serving as the vice president of TPG Haihua (Shanghai) Equity Investment Management Co., Ltd. (德太海華(上海)股權投資管理有限公司), responsible for healthcare investments in Greater China for TPG Capital, a leading global alternative asset firm. Ms. Li previously worked at Shanghai Guijing Investment Management (Limited Partnership) (上海貴景投資中心(有限合夥)). From July 2018 to August 2020, Ms. Li served as an investment manager of Hangzhou Shengding Jikang Equity Investment Management Co., Ltd. (杭州盛鼎濟康股權投資管理有限公司), a healthcare investment platform under Sino-Ocean Capital (遠洋資本). From August 2020 to November 2021, Ms. Li served as the senior investment manager of Shanghai Yunfeng Investment Management Co., Ltd. (上海雲鋒投資管理有限公司). Ms. Li is also a non-executive director of Dingdang Health Technology Group Ltd. (叮噹健康科技集團有限公司) (stock code: 9886 (HKSE)).

Ms. Li obtained a bachelor's degree in chemistry from University of Birmingham in the United Kingdom in July 2014 and a bachelor's degree in chemistry from Sun Yat-sen University (中山大學) in the PRC in September 2014. She further obtained a master's degree in chemistry from Brown University in Rhode Island, the United States in May 2016.

Independent Non-executive Directors

Dr. Ziye ZHAO (趙子夜), is an independent non-executive Director.

For nearly two decades, Dr. Zhao has been deeply immersed in the field of accounting and financial education. He joined Shanghai University of Finance and Economics (上海財經大學) in July 2007 as a lecturer and has been a professor since June 2020. Dr. Zhao is also an independent director and the chairperson of the audit committee of Bright Dairy & Food Co., Ltd. (光明乳業股份有限公司) (stock code: 600597 (SHSE)) and Shanghai Huitong Energy Co., Ltd. (上海匯通能源股份有限公司) (stock code: 600605 (SHSE)). He also served as an independent director and the chairperson of the audit committee of Shanghai Phoenix Enterprise (Group) Co., Ltd. (上海鳳凰企業(集團)股份有限公司) (stock code: 600679 (SHSE)) from February 2016 to January 2022, an independent director and the chairperson of the audit committee of Shanghai Chlor-Alkali Chemical Co., Ltd. (上海氯鹼化工股份有限公司) (stock code: 600618 (SHSE)) from April 2016 to October 2023, and an independent director of Jiangsu Feiliks International Logistics Inc. (江蘇飛力達國際物流股份有限公司) (stock code: 300240 (SZSE)) from May 2017 to May 2023.

Dr. Zhao obtained a bachelor's degree, a master's degree and a doctoral degree all in accounting from Nanjing University in June 2001, June 2004 and June 2007, respectively. Dr. Zhao was granted second prize of National Teaching Achievement Award (國家教學成果獎) by the Ministry of Education in September 2014.

Our Board is of the view that Dr. Zhao has accumulated in-depth knowledge and extensive experience in supervising and monitoring the financial reporting, internal control and other accounting-related matters of listed issuers, and has the relevant accounting or related financial management expertise for the purpose of Rule 3.10(2) of the Listing Rules based, among others, on his relevant experience below:

(i) lecturing and teaching courses related to accounting, auditing, and financial management at Shanghai University of Finance and Economics (上海財經大學); and

(ii) serving as an independent director and the chairperson and/or a member of the audit committee of listed companies, during which Dr. Zhao has been responsible for, among other duties, reviewing the financial statements and accounting policies, monitoring and evaluating the external and internal audit work and internal control of the listed companies, making recommendations on the appointment and replacement of external audit firms through deliberations at the periodic board meetings and committee meetings reviewing and approving annual and interim financial statements, and discussions with the management, other members of the audit committee as well as the external auditors of such companies from time to time.

Dr. Wenfang WU (吳文芳), is an independent non-executive Director.

Dr. Wu possesses with decades of jurisprudence scholarship. Dr. Wu's professional career began as a lecturer at Tianjin Normal University (天津師範大學). She is currently with Shanghai University of Finance and Economics and is a professor of its law school. Dr. Wu is also an independent director of Zhejiang Zomax Transmission Co., Ltd. (浙江中馬傳動股份有限公司)

(stock code: 603767 (SHSE)), Shanghai Chinafortune Co., Ltd. (上海華鑫股份有限公司) (stock code: 600621 (SHSE)), Taicang Zhanxin Adhesive Material Co., Ltd. (太倉展新膠黏材料股份有限公司) and Xinjiang Qianhai United Property & Casualty Insurance Co., Ltd. (新疆前海聯合財產保險股份有限公司).

Dr. Wu obtained a bachelor's degree in economic law from Jiangxi University of Finance and Economics (江西財經大學) in the PRC in July 2000, and a master's degree in economic law from Zhongnan University of Economics and Law (中南財經政法大學) in the PRC in June 2003. She further obtained a doctoral degree in civil and commercial law from Renmin University of China (人民大學) in the PRC in June 2009. She obtained the Legal Professional Qualification Certificate (法律職業資格證書) from the Ministry of Justice of the PRC in March 2004.

Dr. Genhong CHENG, is an independent non-executive Director.

Dr. Cheng has served as a professor at the University of California, Los Angeles since 1996. Dr. Cheng founded the Institute of Systems Medicine at the Chinese Academy of Medical Sciences (中國醫學科學院系統醫學研究所). Beyond his academic and leadership roles, Dr. Cheng possesses extensive experience and deep insight into the pharmaceutical industry. He is the founder of several pharmaceutical companies, including Suzhou Royaltech Med Co., Ltd. (蘇州若泰醫藥科技有限公司), which focuses on CMC development of innovative tumor vaccines and rapid clinical application of advanced cell immunotherapies. Dr. Cheng was also an independent director of Yifan Pharmaceutical Co., Ltd. (億帆醫藥股份有限公司) (stock code: 362019 (SZSE)) from April 2019 to May 2025.

Dr. Cheng obtained a bachelor's degree in 1984 from Wuhan University (武漢大學) in the PRC. He further obtained a doctoral degree in molecular biology from Albert Einstein College of Medicine in the U.S. in June 1990. He subsequently conducted postdoctoral research at The Rockefeller University and the Massachusetts Institute of Technology, respectively. Throughout his career, Dr. Cheng has been honored with numerous scientific awards, including the Stohlman Scholar Award from the Leukemia & Lymphoma Society, and was elected as a fellow of the American Association for the Advancement of Science in 2012 and a fellow of the American Academy of Microbiology in 2019.

SENIOR MANAGEMENT

Our senior management team is responsible for the day-to-day management of our business. The table below shows certain information in respect of the senior management members (other than those who are executive Directors) of our Company:

Name	Age	Position	Date of joining our Company	Date of appointment as our senior management member	Roles and responsibilities
Dr. Haiqing YUAN	60	Chief Operating Officer	May 2017	May 2017	Research and development projects, research and development strategy and daily operation of our Group

Note: Ages are calculated based on the year of birth.

For biographies of Dr. Wu and Dr. Mingyu JIANG, please see "— Directors — Executive Directors."

Dr. Haiqing YUAN, first joined our Group as the Chief Scientific Officer in May 2017 and has been serving as the Chief Operating Officer of our Company since July 2020.

He worked as a research investigator at Allergan plc (stock ticker/code: AGN (NYSE)) from August 2000 to June 2015. From May 2016 to April 2017, Dr. Yuan worked as a senior director at WuXi AppTec (Shanghai) Co., Ltd. (上海藥明康德新藥開發有限公司, a subsidiary of Wuxi AppTec Co., Ltd. (無錫藥明康德新藥開發有限公司) (stock code: 2359 (HKSE)).

Dr. Yuan obtained his bachelor's degree in physical chemistry from Fudan University (復旦大學) in the PRC in July 1988 and his doctoral degree in chemistry in Virginia Polytechnic Institute and State University in the U.S. in August 1998. Dr. Yuan was a post-doctoral associate at department of chemistry and biochemistry of University of Notre Dame from September 1998 to August 1999 and a post-doctoral fellow at Walther Cancer Institute starting from September 1999 before he joined Allergan plc in August 2000.

Save as disclosed above, none of our Directors or senior management members had held any directorship in any public company the securities of which are listed on any securities market in Hong Kong or overseas during the three years immediately preceding the Latest Practicable Date.

As of the Latest Practicable Date and save as disclosed above, (i) none of our Directors or members of the senior management of our Company was related to any other Directors and members of the senior management, and (ii) there was no additional matter with respect to the appointment of the Directors that needs to be brought to the attention of the Shareholders, and there was no additional information relating to the Directors that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

JOINT COMPANY SECRETARIES

Dr. Mingyu JIANG (蔣鳴昱) was appointed as one of our joint company secretaries, with effect from the [**REDACTED**]. For details of his biography, please see "— Directors — Executive Directors" above.

Ms. Wai Yan Leung (梁慧欣) was appointed as one of our joint company secretaries, with effect from the [**REDACTED**]. Ms. Leung currently serves as a manager of corporate services of Vistra Corporate Services (HK) Limited. She has over 17 years of experience in providing company secretarial services and compliance services to listed companies and private companies.

Ms. Leung is currently serving as the company secretary at Akeso, Inc. (康方生物科技(開曼)有限公司) (stock code: 9926 HKSE), and a joint company secretary at Cryofocus Medtech (Shanghai) Co., Ltd. (康灃生物科技(上海)股份有限公司) (stock code: 6922 (HKSE)), Powerlong Real Estate Holdings Limited (寶龍地產控股有限公司) (stock code: 1238 (HKSE)) and Powerlong Commercial Management Holdings Limited (寶龍商業管理控股有限公司) (stock code: 9909 (HKSE)).

Ms. Leung obtained a master of laws majoring in corporate and financial law from The University of Hong Kong and a bachelor's degree in business (administrative management) from University of South Australia. Ms. Leung has been an associate member of The Hong Kong Chartered Governance Institute and an associate member of The Chartered Governance Institute in the United Kingdom since October 2009.

BOARD COMMITTEES

We have established three Board committees, namely the Audit Committee, the Remuneration and Appraisal Committee and the Nomination Committee in accordance with the applicable provisions of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules.

Audit Committee

The Audit Committee consists of three members, namely Dr. Wenfang WU (吳文芳), Ms. Audrey RAO and Dr. Ziye ZHAO. Dr. Ziye ZHAO has been appointed as the chairperson of the Audit Committee and is our independent non-executive Director holding the appropriate professional qualifications. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal control system, oversee the audit process and the existing and potential risks of our Company and perform other duties as assigned by our Board.

Remuneration and Appraisal Committee

The Remuneration and Appraisal Committee consists of three members, namely Dr. Liyang SHI (石莉揚), Dr. Wenfang WU (吳文芳) and Dr. Genhong CHENG. Dr. Genhong CHENG has been appointed as the chairperson of the Remuneration and Appraisal Committee. The primary duties of the Remuneration and Appraisal Committee are to establish and review the remuneration policy and structure for the Directors and senior management and make recommendations on employee benefit arrangement.

Nomination Committee

The Nomination Committee consists of three members, namely Dr. Wenfang WU (吳文芳), Dr. Wu and Dr. Genhong CHENG. Dr. Wenfang WU has been appointed as the chairperson of the Nomination Committee. The primary duties of the Nomination Committee are to make recommendations to our Board on the appointment and removal of Directors of our Company.

BOARD DIVERSITY POLICY

Our Board has adopted a diversity policy to support our strategic goals and sustainable growth. We value diversity in areas such as gender, age, background, experience, and skills. Director candidates are selected based on merit and their alignment with our business needs, with diversity as an important consideration. We place particular emphasis on gender diversity. After [**REDACTED**], we aim to gradually increase the number of female directors by identifying and maintaining a pool of qualified female candidates with diverse expertise. Female investor representatives are also considered, and we promote gender balance in mid- to senior-level recruitment to build a pipeline of future female leaders. We will provide training to high-potential female employees in areas such as operations, management, finance, and compliance, to prepare them for leadership roles. Our Nomination Committee oversees board diversity and will review the policy annually. Progress and measurable outcomes will be disclosed in our corporate governance report.

COMPLIANCE WITH CORPORATE GOVERNANCE CODE

Our Company intends to comply with all code provisions in Part 2 of the Corporate Governance Code after the [**REDACTED**], except for code provision C.2.1, which provides that the roles of chairman and chief executive should not be performed by the same individual.

Dr. Wu currently serves as both chairperson of the Board and CEO. His extensive experience provides strong and consistent leadership and facilitates the efficient execution of our strategies. While this constitutes a deviation from code provision C.2.1, the Board believes this structure will not impair the balance of power and authority, given that: (i) a decision by our Board requires approval by at least a majority of Directors, and our Board comprises three independent non-executive Directors in compliance with the Listing Rules; (ii) Dr. Wu and the other Directors undertake to fulfill their fiduciary duties in the best interests of our Company; and (iii) the operations of the Board comprises experienced individuals who meet regularly to discuss issues affecting our Company. The Board will continue to review whether the separation of these roles is necessary.

KEY TERMS OF EMPLOYMENT CONTRACTS

We normally enter into (i) an employment contract, (ii) a confidentiality agreement, and (iii) a non-competition agreement with our senior management members and other key personnel. Below sets forth the key terms of these contracts we enter into with our senior management and other key personnel.

Confidentiality

The employee shall keep confidential our trade secrets and other proprietary information, specifically technology and operations, technology R&D, production, supplier, sales and marketing, quality control, internal financial and management information, that we designate as confidential. The employee may not disclose, publish, transfer, teach, use for personal gain, or otherwise make any such confidential information or customer trade secrets known to any third party (including competitors) beyond the scope of their employment. This confidentiality obligation survives the termination of the employee's employment.

Non-competition

Within 12 months from the termination or expiration of the employment contract, the employee is prohibited from serving in any capacity for any company globally that competes with us or engages in research, manufacture or commercialization of similar products. During this period, the employee will receive monthly compensation equal to a specified percentage of their average monthly salary over the 12 months immediately preceding termination.

REMUNERATION OF DIRECTORS AND FIVE HIGHEST PAID INDIVIDUALS

Our Directors and senior management members who receive remuneration from our Company are paid in forms of salaries, allowances, discretionary bonuses, share-based payment compensation and other benefits in kind. The remuneration of our Directors and senior management members is determined with reference to their experience, duties and performance and the salaries of comparable companies.

The aggregate amount of salaries, allowances benefits, pension scheme contributions and share-based payment compensation we paid to our Directors in respect of the financial years ended December 31, 2024 and 2025 was approximately RMB15.9 million and RMB21.9 million, respectively. Further information on the remuneration of each Director during the Track Record Period is set out in Note 9 in the Accountants' Report set out in Appendix I to this document.

Under the arrangements currently in force, the aggregate amount of remuneration (excluding any discretionary bonus which may be paid) payable by our Company to our Directors for the financial year ending December 31, 2026 is expected to be approximately RMB27.6 million.

For the financial years ended December 31, 2024 and 2025, the five highest paid individuals of our Company included one Director and two Directors, and the aggregate amount of salaries, allowances, benefits in kind, performance related bonuses, pension scheme contributions and equity-settled share award expense we paid to our five highest paid individuals who are neither Directors nor chief executives of our Company was approximately RMB19.0 million and RMB20.3 million, respectively.

During the Track Record Period, no fees were paid by our Company to any of our Directors (or former Directors) or the five highest paid individuals as an inducement to join our Company or as compensation for loss of office. None of the Directors waived their remuneration during the Track Record Period.

COMPLIANCE ADVISOR

We have appointed Rainbow Capital (HK) Limited as our Compliance Advisor upon the [**REDACTED**] of our H Shares on the Stock Exchange in compliance with Rule 3A.19 of the Listing Rules. The term of the appointment shall commence on the [**REDACTED**] and end on the date on which our Company distributes its annual report in respect of its financial results for the first full financial year commencing after the [**REDACTED**] and this appointment may be subject to extension by mutual agreement.

CONFIRMATIONS FROM OUR DIRECTORS

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in September 2025, and (ii) understands his or her obligations as a director of a [**REDACTED**] issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) that his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules; (ii) that he/she has no past or present financial or other interest in the business of our Company or its subsidiaries or any connection with any core connected person of our Company under the Listing Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointments.

Rule 8.10 of the Listing Rules

Each of our executive and non-executive Directors confirms that as of the Latest Practicable Date, he/she did not have any interest in a business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules.

From time to time our non-executive Directors may serve on the boards of both private and public companies within the broader healthcare and biopharmaceutical industries. However, as these non-executive Directors are not members of our executive management team, we do not believe that their interests in such companies as directors would render us incapable of carrying on our business independently from the other companies in which these non-executive Directors may hold directorships from time to time.